SCHEMBL4171464

SCHEMBL4171464

O=c1[nH]cc(-c2ccco2)c(=O)n1Cc1cc(F)cc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.43
KDM4E B2RXH2 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
PKM P14618 3/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPK1 P28482 2/20 0.40
TSHR P16473 6/20 0.36
LMNA P02545 3/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 3/20 0.36
GAA P10253 2/20 0.36
CASP1 P29466 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HTT P42858 3/20 0.34
F2 P00734 1/20 0.34
POLB P06746 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4165444 0.89 ALDH1A1 (0.51) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4171397 0.85 ALDH1A1 (0.50) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4160559 0.79 ALDH1A1 (0.46) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4162501 0.78 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4160886 0.78 P2RX4 (0.45) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4179886 0.74 TDP1 (0.43) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL28374611 0.73 STK4 (0.36) ALDH1A1KDM4ESMN1; SMN2PKMMEN1
SCHEMBL4174008 0.72 DBH (0.36) KMT2AIDO1GRIN1GRIN2B
SCHEMBL8225968 0.70 ADORA2A (0.36) ALDH1A1KDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL4174300 0.69 ALDH1A1 (0.47) ALDH1A1KDM4EMEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US claimed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO claimed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2009-06-11 US disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed
WO-2007122634-A2 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS JUBILANT BIOSYS LIMITED (IN) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149485-A1 PYRIMIDINEDIONES AS TYROSINE KINASE INHIBITORS TK1, LCK, FYN ALDH1A1 1813/4885KDM4E 2284/4885SMN1; SMN2 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.